BWAY BrainsWay Ltd.

On August 12, BrainsWay Ltd. (NASDAQ:BWAY) reported second-quarter 2026 results that make the neurostimulation company look less like a niche medtech story and more like a genuine growth compounder. Revenue climbed 35% year over year to a record $17.1 million, and adjusted EBITDA more than doubled to $3.5 million. The company shipped 125 Deep TMS […]

Investors need to pay close attention to BWAY stock based on the movements in the options market lately.

The mean of analysts' price targets for Brainsway (BWAY) points to a 30.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Brainsway (BWAY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Here is how Allogene Therapeutics (ALLO) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.

Brainsway (NASDAQ:BWAY) reported second-quarter revenue growth of 35% and raised its full-year 2026 revenue outlook, citing continued demand for its Deep TMS systems, expanding reimbursement for its accelerated SWIFT treatment protocol and growth in its installed base. Revenue for the three months

Company raises full-year 2026 guidance to $68-$70 million on strong SWIFT protocol adoption and expanding reimbursement coverage.

BWAY earns Bull of the Day on expanding Deep TMS adoption, while LULU lands Bear of the Day as slowing growth and falling estimates weigh on outlook.

Brainsway shares have rallied more than 60% this year, with more bullish tailwinds at its back.

Brainsway (BWAY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Finding the best Zacks Rank #1 (Strong Buy) stocks out of a group of over 200 highly-ranked stocks to consider buying as Q2 earnings season ramps up.

Terumo stands out as medical products companies navigate cost pressures with innovation, pricing actions and demand for advanced diagnostics supporting growth.

BWAY, HTLD and NCNO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 14th, 2026.